HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Relay Therapeutics (NASDAQ:RLAY) and raises the price target from $30 to $33.
October 17, 2023 | 5:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Relay Therapeutics' price target has been raised from $30 to $33 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Relay Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100